Enliven Therapeutics, Inc. (ELVN) — Capital Expenditures
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $158.0K | +259.1% |
| 2024 | $44.0K | -70.5% |
| 2023 | $149.0K | -75.7% |
| 2022 | $612.0K | +5000.0% |
| 2021 | $12.0K | -33.3% |
| 2020 | $18.0K | -87.1% |
| 2019 | $140.0K | — |
| Fiscal Year | Capital Expenditures | Change YoY |
|---|---|---|
| 2025 | $158.0K | +259.1% |
| 2024 | $44.0K | -70.5% |
| 2023 | $149.0K | -75.7% |
| 2022 | $612.0K | +5000.0% |
| 2021 | $12.0K | -33.3% |
| 2020 | $18.0K | -87.1% |
| 2019 | $140.0K | — |